Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (74.1%), Europe (17%) and other (8.9%).

Number of employees : 13 600 people.
Sales per Business
20192020Delta
USD (in Million)%USD (in Million)%
Innovative Medicines22,449100.6%24,689100.2% +9.98%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States16,64574.6%18,21773.9% +9.44%
Europe3,81117.1%4,13516.8% +8.5%
Other International1,9938.9%2,3379.5% +17.26%
Managers and Directors
NameAgeSinceTitle
Daniel O'Day552019Chairman & Chief Executive Officer
Andrew Dickinson502019Chief Financial Officer
William Lee652015Executive Vice President-Research
Merdad Parsey-2019Chief Medical Officer
Brett Pletcher52-Secretary, Chief Compliance Officer & Executive VP
Gayle Edlund Wilson772001Independent Director
John Francis Cogan, Dr.722013Lead Independent Director
Richard J. Whitley, Dr.732008Independent Director
Kevin E. Lofton652009Independent Director
Per Wold-Olsen732010Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,256,593,156 1,252,149,307 99.6% 0 0.0% 99.6%
Shareholders
NameEquities%
Capital Research & Management Co. (Global Investors) 121,672,399 9.71%
The Vanguard Group, Inc. 97,128,178 7.75%
Capital Research & Management Co. 64,780,000 5.17%
SSgA Funds Management, Inc. 55,206,559 4.40%
Capital Research & Management Co. (International Investors) 46,548,996 3.71%
Capital Research & Management Co. (World Investors) 38,534,588 3.07%
BlackRock Fund Advisors 31,581,841 2.52%
Geode Capital Management LLC 20,078,920 1.60%
Dodge & Cox 17,107,888 1.36%
Northern Trust Investments, Inc.(Investment Management) 15,243,829 1.22%
Holdings
NameEquities%Valuation
Galapagos NV (GLPG) 16,707,47725.5%1,746,432,571 USD
Arcus Biosciences, Inc. (RCUS) 13,913,02921.4%483,199,497 USD
Allogene Therapeutics, Inc. (ALLO) 7,486,6895.34%259,788,108 USD
Jounce Therapeutics, Inc. (JNCE) 5,539,72713.9%62,598,915 USD
Agenus Inc. (AGEN) 11,111,1115.84%40,888,888 USD
HOOKIPA Pharma Inc. (HOOK) 2,092,7998.12%22,372,021 USD
Sierra Oncology, Inc. (SRRA) 348,0173.15%5,039,286 USD
Markets and indexes
-
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 100, S&P 500, Stoxx Americas 100, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  GILD:US
- Reuters Code :  GILD.O
- Datastream Code :  @GILD
Company contact information
Gilead Sciences, Inc.
333 Lakeside Drive
CA 94404 San Mateo, California


Phone : +1 650 574 3000
Fax : +1 650 578 9264
web site : http://www.gilead.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Gilead Sciences, Inc.
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.10.92%81 201
VERTEX PHARMACEUTICALS-10.31%55 106
WUXI APPTEC CO., LTD.0.64%50 791
REGENERON PHARMACEUTICALS-4.46%48 070
BEIGENE, LTD.16.60%27 598
BIONTECH SE18.01%23 164
GENMAB A/S-22.80%19 938
ARGENX SE-1.24%14 603
HUALAN BIOLOGICAL ENGINEERING INC.-1.87%11 642
MIRATI THERAPEUTICS, INC.-13.23%9 650
NEUROCRINE BIOSCIENCES, INC.-2.73%8 758
ASCENDIS PHARMA A/S-11.91%7 934
ULTRAGENYX PHARMACEUTICAL INC.-14.40%7 933
FATE THERAPEUTICS, INC.-8.01%7 845
ACCELERON PHARMA INC.-0.12%7 738
DENALI THERAPEUTICS INC.-27.13%7 385
ARROWHEAD PHARMACEUTICALS, INC.-10.07%7 162
EXELIXIS, INC.11.26%6 967
GW PHARMACEUTICALS PLC86.24%6 738
SAREPTA THERAPEUTICS, INC.-50.27%6 734
BIOCON LIMITED-15.21%6 383